CNTX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• CTIM-76: Integral Molecular Collaboration and Licensing Agreement

• In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”) for the development of a CLDN6 bsAb for cancer therapy. On February 29, 2024, we further amended (the "Second Amendment") the Research Collaboration an…

• amended) with Integral to reflect updated financial terms. In the course of our further due diligence review of CTIM-76, we determined that certain of the licensed rights under the Integral License Agreement may incorporate intellectual property rights currently held by a third party. Specifically, …

• CTIM-76 expenditures increased by $1.2 million primarily due to an increase of $1.1 million in clinical costs related to the CTIM-76 Phase 1 trial. CT-95 expenses increased by $0.6 million primarily due to an increase of $0.9 million in clinical costs related to the CT-95 Phase 1 trial, which were p…

• General and administrative expenses increased by approximately $0.3 million for the three months ended March 31, 2026 as compared to the same period in 2025. The increase was primarily driven by a $0.2 million increase in salaries and personnel related costs, mainly as a result of higher share-based…

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”) for the development of a CLDN6 BsAb for cancer therapy. On February 29, 2024, we further amended (the "Second Amendment") the Research Collaboration an…

• United States and certain foreign jurisdictions expiring in January 2034, and then in 2025 became aware of a patent that issued in the United States expiring in March 2042, in each instance that potentially covers certain parts of the intellectual property included in CTIM-76.While we believe we wil…

• CTIM-76 expenditures increased by $0.2 million due to an increase of $0.6 million in clinical costs, partially offset by a decrease of $0.4 million in preclinical and contract manufacturing costs. CT-95 expense of $1.2 million for the three months ended September 30, 2025 primarily represents $1.0 m…

• General and administrative expenses did not materially change for the three months ended September 30, 2025 as compared to the same period in 2024.

• Comparison of the Nine Months Ended September 30, 2025 and 2024

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• On February 4, 2026, the Vladimir Gusinsky Revocable Trust filed a stockholder class action complaint (the “Action”) against us and our directors in the Court of Chancery of the State of Delaware (the “Court”) asserting that (i) Article V, Section 2 of our Amended and Restated Certificate of Incorpo…

• On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court regarding the Action, and on March 11, 2026, the Court approved the Stipulated Judgment, pursuant to which Article V, Section 2 and Article VI, Section 1 of the Certificate of Incor…

• On April 30, 2026, the Company entered into a letter agreement (the “Letter Agreement”), pursuant to which a third party service provider (the “Provider”) of the Company agreed to pay the Mootness Fee (as defined below) in full on behalf of the Company.

• On April 30, 2026, the Court granted a Stipulation and Proposed Order Closing the Case (the “Stipulated Order”). The Stipulated Order requires the payment of $850,000 in fees and expenses to plaintiff’s counsel in the Action (the “Mootness Fee”). The Court was not asked to review, and did not pass j…

• On May 1, 2026, the Provider paid the Mootness Fee in full pursuant to the Letter Agreement. The Action will be closed after the Court is informed a quorum was achieved at the Company’s 2026 annual meeting of stockholders, which is scheduled to be held on June 24, 2026.

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• are not presently a party to any material legal proceedings.

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• On November 7, 2022, we entered into a License Agreement (the “CTIM-76 Lonza License Agreement”) with Lonza Sales AG (“Lonza”) related to CTIM-76. On November 3, 2025, we amended the CTIM-76 Lonza License Agreement (the

• “First CTIM-76 License Amendment”) with Lonza to clarify the intent of certain provisions and to update certain of the licensed rights described in the appendices to the CTIM-76 Lonza License Agreement.

• On November 3, 2025, we entered into a License Agreement (the “CT-202 Lonza License Agreement”) with Lonza related to CT-202 in connection with the Development and Manufacturing Services Agreement between Lonza, Lonza AG and the Company, dated as of November 7, 2022 and as amended on January 9, 2025…

• We shall pay certain royalties and annual payments in respect of the manufacturing and sale of CT-202, which amounts shall be determined by the party manufacturing CT-202 and include a potential annual payment of less than $500,000 and a royalty on net sales in a range between 0% and a low single di…

• The CT-202 Lonza License Agreement continues until terminated, and we or Lonza may terminate the CT-202 Lonza License Agreement for uncured material breaches or insolvency of the other party. We can unilaterally terminate the CT-202 Lonza License Agreement with prior written notice to Lonza, and Lon…